Insights on where healthcare gaps create opportunity
Exploring the ideas, innovations, and healthcare system changes shaping better decisions, better care, and better adoption.
Explore news and insights below
NHS scales mailed HPV self-sampling to reach four million overdue screens, shifting cervical screening into decentralized care
England's decision to mail at-home HPV swabs to women who have missed invitations turns a persistent public-health gap into a large, procurement-driven market. For investors, the move accelerates demand for self-collection kits, laboratory capacity, logistics and digital follow-up services that close the screening-to-treatment loop.
Essity’s $284M Brazil buy is a play for scale in femcare — strategic implications for investors and innovators
Essity’s agreement to acquire three high-volume period-care labels and local manufacturing in Brazil is more than routine consolidation; it signals a targeted push to control supply, distribution, and innovation levers in one of the world’s largest femcare markets. For investors, the deal highlights where capital will flow next in women's hygiene: scale-enabled product evolution, supply-chain modernization, and partnership opportunities for nimble femtech entrants.
AU and WHO reset the playbook for African health systems, creating clearer pathways for women's health investment
The renewed AU–WHO memorandum of understanding turns continent-level policy alignment into a practical set of priorities that lower structural barriers for investors in maternal and reproductive health, local pharma, digital platforms, and workforce solutions. Investors should reweight exposure to companies and consortia positioned to deliver on RMNCAH, local manufacturing, regulatory harmonization, and emergency-resilient services.
Public funding is pivoting menopause femtech from consumer demos to clinical and workplace validation
A new cross-border EU-backed program is using regional healthcare partners to test market-ready menopause solutions, creating early procurement and evidence pathways that reduce adoption risk. For investors this signals a shift toward femtech products that must prove clinical and implementation value, not just consumer traction.
AI-matched group therapy for women attracts public grant, signals a scalable route into unmet mental health demand
A UK startup received a public accelerator award to build AI-driven cohort matching and expand affordable virtual group therapy for women. For investors, the prize is not the cash but the combination of early outcome signals, a low-price point, and a playbook for scaling scarce therapist time.
Public grant propels an early bet on continuous hormone sensing — why investors should pay attention
An Estonia-based femtech startup has won a €700K public grant to advance a wearable patch that samples interstitial fluid for multiple daily hormone readings; the award de-risks core sensor work but leaves clinical and commercial hurdles ahead. For investors, the key questions are technical validation of the bioselective layer, regulatory pathway choices, and whether continuous hormone data creates durable clinical and consumer demand.
ESHRE 2026: A turning point — IVF effectiveness is rising while cost and environment become the new bottlenecks
Clinical outcomes presented at ESHRE show modern lab practice has decoupled single-embryo transfer from lower success rates, shifting the commercial opportunity from embryo-number to cost, uterine health, and environmental diagnostics. Investors should reweight toward technologies that cut per-baby cost, expand FET capacity, and address non-oocyte biological risks.
NHS scales mailed HPV self-sampling to reach four million overdue screens, shifting cervical screening into decentralized care
England's decision to mail at-home HPV swabs to women who have missed invitations turns a persistent public-health gap into a large, procurement-driven market. For investors, the move accelerates demand for self-collection kits, laboratory capacity, logistics and digital follow-up services that close the screening-to-treatment loop.
Read more →Essity’s $284M Brazil buy is a play for scale in femcare — strategic implications for investors and innovators
Essity’s agreement to acquire three high-volume period-care labels and local manufacturing in Brazil is more than routine consolidation; it signals a targeted push to control supply, distribution, and innovation levers in one of the world’s largest femcare markets. For investors, the deal highlights where capital will flow next in women's hygiene: scale-enabled product evolution, supply-chain modernization, and partnership opportunities for nimble femtech entrants.
Read more →AU and WHO reset the playbook for African health systems, creating clearer pathways for women's health investment
The renewed AU–WHO memorandum of understanding turns continent-level policy alignment into a practical set of priorities that lower structural barriers for investors in maternal and reproductive health, local pharma, digital platforms, and workforce solutions. Investors should reweight exposure to companies and consortia positioned to deliver on RMNCAH, local manufacturing, regulatory harmonization, and emergency-resilient services.
Read more →Public funding is pivoting menopause femtech from consumer demos to clinical and workplace validation
A new cross-border EU-backed program is using regional healthcare partners to test market-ready menopause solutions, creating early procurement and evidence pathways that reduce adoption risk. For investors this signals a shift toward femtech products that must prove clinical and implementation value, not just consumer traction.
Read more →AI-matched group therapy for women attracts public grant, signals a scalable route into unmet mental health demand
A UK startup received a public accelerator award to build AI-driven cohort matching and expand affordable virtual group therapy for women. For investors, the prize is not the cash but the combination of early outcome signals, a low-price point, and a playbook for scaling scarce therapist time.
Read more →Public grant propels an early bet on continuous hormone sensing — why investors should pay attention
An Estonia-based femtech startup has won a €700K public grant to advance a wearable patch that samples interstitial fluid for multiple daily hormone readings; the award de-risks core sensor work but leaves clinical and commercial hurdles ahead. For investors, the key questions are technical validation of the bioselective layer, regulatory pathway choices, and whether continuous hormone data creates durable clinical and consumer demand.
Read more →ESHRE 2026: A turning point — IVF effectiveness is rising while cost and environment become the new bottlenecks
Clinical outcomes presented at ESHRE show modern lab practice has decoupled single-embryo transfer from lower success rates, shifting the commercial opportunity from embryo-number to cost, uterine health, and environmental diagnostics. Investors should reweight toward technologies that cut per-baby cost, expand FET capacity, and address non-oocyte biological risks.
Read more →Stay Informed
Women's health is moving fast. Keep up.
Get Fern's latest research, investment commentary, and event invitations delivered to your inbox.